scholarly journals Is there a role of Eastern Europe in cancer biomarkers for personalized cancer medicine?

2014 ◽  
Vol 14 (2-3) ◽  
pp. 85-86
Author(s):  
I. Berindan-Neagoe ◽  
A. Paradiso
Keyword(s):  
Eastern Europe ◽  
Cancer Biomarkers ◽  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

scholarly journals Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?

2021 ◽  
Vol 11 (8) ◽  
pp. 741
Author(s):  
Katherine Hicks-Courant ◽  
Jenny Shen ◽  
Angela Stroupe ◽  
Angel Cronin ◽  
Elizabeth F. Bair ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Media Coverage ◽  
Disease Risk ◽  
Federal Drug Administration ◽  
Personalized Cancer Medicine ◽  
The Media ◽  
Cancer Medicine ◽  
Media Reports ◽  
Personalized Cancer ◽  
Standard Tests

Background: Given that media coverage can shape healthcare expectations, it is essential that we understand how the media frames “personalized medicine” (PM) in oncology, and whether information about unproven technologies is widely disseminated. Methods: We conducted a content analysis of 396 news reports related to cancer and PM published between 1 January 1998 and 31 December 2011. Two coders independently coded all the reports using a pre-defined framework. Determination of coverage of “standard” and “non-standard” therapies and tests was made by comparing the media print/broadcast date to the date of Federal Drug Administration approval or incorporation into clinical guidelines. Results: Although the term “personalized medicine” appeared in all reports, it was clearly defined only 27% of the time. Stories more frequently reported PM benefits than challenges (96% vs. 48%, p < 0.001). Commonly reported benefits included improved treatment (89%), prediction of side effects (30%), disease risk prediction (33%), and lower cost (19%). Commonly reported challenges included high cost (28%), potential for discrimination (29%), and concerns over privacy and regulation (21%). Coverage of inherited DNA testing was more common than coverage of tumor testing (79% vs. 25%, p < 0.001). Media reports of standard tests and treatments were common; however, 8% included information about non-standard technologies, such as experimental medications and gene therapy. Conclusion: Confusion about personalized cancer medicine may be exacerbated by media reports that fail to clearly define the term. While most media stories reported on standard tests and treatments, an emphasis on the benefits of PM may lead to unrealistic expectations for cancer genomic care.

scholarly journals Personalized cancer medicine and the future of pathology

2011 ◽  
Vol 460 (1) ◽  
pp. 3-8 ◽  
Author(s):  
H. Moch ◽  
P. R. Blank ◽  
M. Dietel ◽  
G. Elmberger ◽  
K. M. Kerr ◽  
...  
Keyword(s):  
Personalized Cancer Medicine ◽  
The Future ◽  
Cancer Medicine ◽  
Personalized Cancer

scholarly journals The Surgical Specimen Is the Personalized Part of Personalized Cancer Medicine

2009 ◽  
Vol 16 (8) ◽  
pp. 2079-2080 ◽  
Author(s):  
Carolyn C. Compton
Keyword(s):  
Surgical Specimen ◽  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

Enabling personalized cancer medicine through analysis of gene-expression patterns

Nature ◽  
2008 ◽  
Vol 452 (7187) ◽  
pp. 564-570 ◽  
Author(s):  
Laura J. van 't Veer ◽  
René Bernards
Keyword(s):  
Gene Expression ◽  
Expression Patterns ◽  
Gene Expression Patterns ◽  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

scholarly journals An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Yin Liu ◽  
Teng Fei ◽  
Xiaoqi Zheng ◽  
Myles Brown ◽  
Peng Zhang ◽  
...  
Keyword(s):  
Drug Combination ◽  
Combination Therapies ◽  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

scholarly journals Getting to personalized cancer medicine

Cancer ◽  
2007 ◽  
Vol 110 (8) ◽  
pp. 1641-1643 ◽  
Author(s):  
Carolyn Compton
Keyword(s):  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

Personalized Cancer Medicine

2012 ◽  
pp. 257-282 ◽  
Author(s):  
Christina Perry ◽  
Rebeka Sultana ◽  
Srinivasan Madhusudan
Keyword(s):  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

scholarly journals Lymphadenectomy in elderly patients with high-intermediate-risk, high-risk or advanced endometrial cancer: Time to move from personalized cancer medicine to personalized patient medicine!

2019 ◽  
Vol 45 (8) ◽  
pp. 1388-1395 ◽  
Author(s):  
Adélaïde Racin ◽  
Emilie Raimond ◽  
Sofiane Bendifallah ◽  
Krystel Nyangoh Timoh ◽  
Lobna Ouldamer ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
High Risk ◽  
Elderly Patients ◽  
Intermediate Risk ◽  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

Cancer Genomics: Technology, Discovery, and Translation

2012 ◽  
Vol 30 (6) ◽  
pp. 647-660 ◽  
Author(s):  
Ben Tran ◽  
Janet E. Dancey ◽  
Suzanne Kamel-Reid ◽  
John D. McPherson ◽  
Philippe L. Bedard ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Somatic Mutations ◽  
Cancer Genomics ◽  
Tumor Biology ◽  
Genetic Aberrations ◽  
Personalized Cancer Medicine ◽  
Early Results ◽  
Cancer Medicine ◽  
Management Recommendations ◽  
Personalized Cancer

In recent years, the increasing awareness that somatic mutations and other genetic aberrations drive human malignancies has led us within reach of personalized cancer medicine (PCM). The implementation of PCM is based on the following premises: genetic aberrations exist in human malignancies; a subset of these aberrations drive oncogenesis and tumor biology; these aberrations are actionable (defined as having the potential to affect management recommendations based on diagnostic, prognostic, and/or predictive implications); and there are highly specific anticancer agents available that effectively modulate these targets. This article highlights the technology underlying cancer genomics and examines the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations. Finally, drawing from experiences gained in a feasibility study of somatic mutation genotyping and targeted exome sequencing led by Princess Margaret Hospital–University Health Network and the Ontario Institute for Cancer Research, the processes, challenges, and issues involved in the translation of cancer genomics to the clinic are discussed.

Sign in / Sign up

Export Citation Format

Share Document